Skip to main content

Funding opportunities

This page contains a list of current funding opportunities offered by other societies, associations and organisations.  If you would like to advertise a funding opportunity on this page, please contact our Education & Careers Officer, Eolan Healy.

Funding opportunities are removed once the application deadline has passed.

You may also find it useful to have a look at our jobs board. In addition to the specific opportunities below, the following websites contain information on sources of funding.

For information relating to funding postgraduate courses and research in the UK:

For information on research funding and fellowship opportunities at all levels in the UK and internationally:

Funding Opportunities

Realignment of Established Targets and Mechanisms for Delaying or Reversing T1D


There are no cures for T1D, an autoimmune disease characterized by an immune-mediated loss of pancreatic beta cell mass and function, resulting in insulin deficiency and dependency. While exogenous insulin therapy is the only established treatment, people with T1D require constant glucose management. Only 17 percent of youth and 21 percent of adults achieve optimal glycemic outcomes, and people living with T1D face significant risk of long-term complications, mental burden of 24/7/365 disease management, financial burden due to medical care, and loss of income and productivity. According to the CDC’s 2020 National Diabetes Statistics Report, 1.6 million Americas live with T1D in the United States, an increase of nearly 30% from 2017, with cases growing most sharply among diverse populations. New interventions to prevent, slow, or halt disease progression are urgently needed to improve outcomes for the increasing number of people diagnosed with T1D each year.

The JDRF Cures Program strategy for disease-modifying therapies is to develop treatments that prevent, halt, or reverse disease progression by rebalancing the immune system and preserving or regrowing beta cells. T1D is a complex disease, suggesting success in treatment and prevention will be based upon a variety of targets and pathways. In a recent phase 2 clinical study, efficacy in the reduction of insulin dependency was observed using golimumab, a TNFα inhibitor with FDA approval for autoimmune indications such as forms of arthritis and Crohn’s disease. Therefore, there is a clear precedent for the successful realignment of therapeutics from other autoimmune diseases for assessment in T1D. In addition, checkpoint inhibitor therapy for cancer, such as the anti-PD1 monoclonal antibody, is associated with increased diagnosis of T1D within 3 months of treatment, indicating a connection between immune interventions in other diseases and the onset of autoimmune diabetes. This highlights an opportunity to explore the onset of T1D from novel perspectives and disciplines, with the potential to identify previously unidentified targets or strategies for disease modifying therapies.

Funding Opportunity Description
JDRF, the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D), aspires to establish new disease-modifying therapy clinical trials, and to foster the development of disease modifying therapies for T1D. For this endeavor to succeed, it is vital to promote and advance a broad discovery and preclinical research pipeline that is rapidly translatable to clinical trials. Given the potential for overlap in the biological processes of different diseases, research currently underway in fields such as autoimmunity, metabolism, cancer immunology, and various others may represent untapped lines of inquiry for discovery and preclinical research in T1D. The goal of this invitation is to accelerate therapy development by increasing the number of identified candidates for clinical interrogation in T1D through the realignment of targets and mechanisms under investigation in other fields or disease indications. Projects considered for funding will represent innovative ideas, perspectives, and approaches in T1D
research, with the objective of providing a significant acceleration and expansion of discovery research and preclinical development. Studies investigating human and mouse gene and protein targets, pharmacological evaluation of existing interventions, and the assessment of mechanisms that play a role in related diseases in T1D-relevent model systems are of particular interest.

Applicant Eligibility

  • We welcome LOIs from investigators, pre-formed teams, organizations, and companies with demonstrated expertise to carry out the proposed research.
  • Applications may be submitted by domestic and foreign non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, industry, units of state and local governments, and eligible agencies of the federal government. Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent and have a faculty position or equivalent at a college, university, medical school, or other research facility.
  • There are no citizenship requirements for this program. To assure continued excellence and diversity among applicants and awardees, JDRF welcomes applications from all qualified individuals and encourages applications from persons with disabilities, women, and members of minority groups underrepresented in the sciences.
  • Collaborative projects combining the expertise and/or resources of multiple research groups are highly encouraged, as are international collaborations and other partnerships that bring together distinct expertise and abilities. Preference will be given to proposals that combine the expertise of laboratories new to the T1D field with those already established in the study of T1D. In addition, JDRF will work to connect laboratories new to the T1D field with potential collaborators and resources as needed.
Closing Date:
BBSRC/NC3Rs joint call: development of next generation non-animal technologies

The grant
A joint £4M call funded by UKRI-BBSRC and the NC3Rs aims to support the development and use of next generation non-animal technologies in bioscience research.

The funders are looking to support proposals that:

  •    Develop the next generation of non-animal technologies that mimic the physiological environment enabling a whole system/ multi-system approach for discovery and translational science.
  •    Enhance the capacity and confidence in non-animal technologies.
  •    Establish partnerships between academia, the SME sector, and industry.

The scope
Proposals must fall within the BBSRC’s remit to qualify for funding. The research supported should have the realistic possibility of replacing the use of specific in vivo models or animal studies in line with the NC3Rs mission.

Example research areas for the development of non-animal technologies include enabling:

  • The mechanistic understanding of ageing across the life-course.
  • The development and testing of novel veterinary vaccines.
  • A more accurate study of microbial diversity and functions of the microbiota on both specific organs and whole systems.
  • The study of complex neurological pathways and systems across the life-course.
  • These examples are provided to help you develop your ideas. These should not lead or limit the scope and ambition of planned applications.
Closing Date:
Coeliac UK basic science research call 2022

After a number delays due to the pandemic, Coeliac UK finally held its long awaited science workshop in March of this year. The research community came together to identify basic science projects that will improve our understanding of coeliac disease and its association with other autoimmune diseases, so that one day we may be able to prevent or even cure coeliac disease.

Researchers are invited to submit an application to this call that will underpin Coeliac UK’s top ten research priorities, in particular the six priorities that were the focus of the science workshop:

  • Finding the triggers for coeliac disease. We know you need certain genetics and gluten to develop coeliac disease but on their own this is not enough. What are the other triggers? Do they determine when someone will develop coeliac disease and/or predict how severe disease associated symptoms or complications will be?
  • Understanding neurological forms of coeliac disease. What is the spectrum of neurological forms of coeliac disease and how does neurological dysfunction develop?
  • Understanding the link between coeliac disease and other conditions. How can we better understand the associations between coeliac disease and other conditions and what factors influence the risk of developing such conditions?
  • Finding a cure for coeliac disease. How can coeliac disease be cured so that consideration of a gluten free diet is no longer necessary?
  • Preventing the onset of coeliac disease. How can coeliac disease and associated complications be prevented in genetically vulnerable individuals?
  • Understanding the causes of refractory coeliac disease. How can we better understand the causes of refractory coeliac disease types I and II and use this understanding to develop and improve diagnosis and treatment?
Closing Date:
Coeliac UK
Coeliac UK research call into coeliac disease in children and young people 2022

Coeliac UK is delighted to be able to offer this pilot/proof of concept grant for research into coeliac disease in children and young people. Researchers are invited to submit applications to this call that will underpin Coeliac UK’s top ten research priorities.

Their research priorities cover a range of key areas including prevention, diagnosis, management and understanding the link between coeliac disease and other conditions, including neurological forms of coeliac disease.

Applications with consideration given to a collaborative project are very much welcome.

Purpose of research
Coeliac UK invests in research and services to make life better for people who can’t eat gluten. They support and share research that will positively change health outcomes for our beneficiaries; improve diagnosis, improve management and care and understand cause/effects - and one day overcoming coeliac disease.


Closing Date:
Coeliac UK
Olive Ayoub Intermediate / Late-Stage Fellowship

The Olive Ayoub Fellowship
The Olive Ayoub Fellowship was established through a generous legacy bequeathed to SRUK in the will of Mrs. Olive Ayoub.

The Intermediate to Late-Stage Fellowship
The Olive Ayoub Intermediate to Late-Stage Fellowship will provide up to £600,000 of funding with the aim of enabling one exceptional non-tenured postdoctoral researcher working in scleroderma or a related field to transition from postdoc to research leader.


  • Four years’ salary for the fellow at 100% cost
  • Up to £30,000 per year in consumables
  • Stipend for a three-year PhD studentship to assist and carry out a research project relevant to the research programme.  


  • Applicants must have a minimum of 3 years and a maximum of 6 years’ experience post-PhD; allowances will be made for time away from research for example due to maternity leave or serious illness.
  • Applicants must currently be working on research either within the field of scleroderma or a closely related/ or translatable field.
  • Applicants must not currently hold a tenured position at a university/ research institution either within the UK or overseas.
  • Applicants based outside of the UK may apply for the fellowship provided the research will be conducted at a UK based institution, which will sponsor their fellowship application. PhD candidates must be UK based.
  • Applicants must provide evidence of support from their host organization (UK based)
  • Proposals must be relevant to one or more themes of the SRUK Research Strategy. 
Closing Date:
Scleroderma and Raynaud’s UK
BMA Foundation for Medical Research – grant categories 2021

All the BMA Foundation for Medical Research grants have National Institute for Health Research (NIHR) partnership status.

Closing Date:
British Medical Association
Medical Research Council (MRC) - variety of fellowships, career development awards and research grants

A variety of fellowships, career development awards and research grants opportunities offered by the Medical Research Council.

Closing Date:
Medical Research Council
MS Society 2022 research awards

The MS Society are the largest charitable funder of multiple sclerosis (MS) research in the UK. The following research awards will be available in 2022.

Catalyst Awards

Catalyst Awards provide 12 months and up to £50,000 support for a short-term, small-scale pilot or proof of concept research project. Two rounds of Catalysts Awards will run in 2022, with the applications for the first round opening on 31 January and closing on 27 April. The second round will open in mid-June.

Project Awards and Career Development Awards

Project Awards to provide support for a time-limited research project designed to answer a single question or a small group of related questions. Career Development Awards include PhD Fellowships and Early Career Fellowships and aim to attract and retain talented researchers who want to build a successful career in MS research. Applications for Project Awards and Career Development Awards will open in early March and close on 7 June 2022.

You can find more information about MS Society funding schemes, eligibility and the application process on their website, or contact

Closing Date:
Varied Travel Grants Programme

Each quarter, offers a travel grant up to £500 to help cover the cost of attending a conference.

These travel grants are open to PhD candidates, lab managers, and post-docs from academic research institutions in the US or Europe. The grant is intended to help cover the costs of registration, accommodation, and travel to a conference of choice.

Closing Date:
HIC-Vac Training Funding

Training grants of up to £5000 are available to help HIC-Vac members pursue training opportunities that will contribute to their continued professional development. This can include (but is not limited to):

  • attending courses or workshops  
  • laboratory exchange/work shadowing
  • attending an international conference to present a talk
Closing Date: